Beam Therapeutics Sues Chinese Rivals Over Alleged Theft of Base Editing Secrets

Key points

• Beam Therapeutics filed a lawsuit on September 25, 2026, in the U.S. District Court for the District of Massachusetts.
• The suit names Zi Jun 'Emma' Wang, Yuxuan 'Jensen' Wu, YolTech Therapeutics, and Serapha Bio as defendants.
• Beam alleges Wang secretly founded YolTech in July 2021 while still employed by Beam, using stolen data to develop a competing base editing therapy.
• Serapha Bio, which raised $230 million and is merging with Boundless Bio, licensed the rival therapy from YolTech and denies the claims.
• The competing therapy, SERP-01, targets the same genetic mutation in the SERPINA1 gene as Beam's lead candidate, BEAM-302.

Background

This dispute follows a recent patent victory for Prime Medicine against Beam Therapeutics over a similar collaboration agreement. The current case highlights ongoing tensions between U.S. and Chinese biotech firms regarding intellectual property. Beam's lead candidate, BEAM-302, is currently in clinical trials for alpha-1 antitrypsin deficiency, a rare disease affecting the lungs and liver.

How outlets are covering it

Fierce Biotech and Bloomberg Law emphasize the alleged theft of trade secrets and the structural similarities between the competing therapies. STAT frames the dispute within the broader context of escalating tensions between American and Chinese biotech companies. BioPharma Dive highlights the financial backing of Serapha Bio and its plans for a reverse merger, noting that Serapha has categorically denied the claims. All sources agree on the core allegations but differ in emphasis, with some focusing on the legal details and others on the industry implications.

Why it matters

The outcome of this lawsuit could set a precedent for intellectual property protection in gene editing, particularly regarding cross-border collaboration and the use of trade secrets. It may also impact the development timelines and regulatory approvals for competing therapies targeting rare diseases.

What to watch

The case will proceed in the U.S. District Court for the District of Massachusetts. Serapha Bio plans to start a Phase 2/3 trial of SERP-01 later this year or in early 2027. Beam Therapeutics is seeking court intervention to stop the misuse of its trade secrets and recover damages.